Ocugen (OCGN) announced updates to its Retina Scientific Advisory Board, SAB, and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company’s internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years. New SAB members include: Jeffrey Heier, MD; Peter Kaiser, MD; Arshad Khanani, MD. Vijay Tammara, PhD, has joined Ocugen in the newly created position of Chief Development Officer. Abhi Gupta, MBA, has been named Executive Vice President, Commercial and Business Development, following the retirement of Mike Shine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema
- Ocugen announces first patient dosed in Phase 2/3 GARDian3 trial for OCU410ST
- Largest borrow rate increases among liquid names
- Ocugen Granted Extension to Meet Nasdaq Listing Requirements
- Ocugen’s Strategic Spinout and NeoCart Platform Propel Buy Rating